AFP DEPARTMENT COLLECTION
This department includes information about new drugs from the perspective of the five attributes to be considered when weighing the advantages of one drug over another: Safety, Tolerability, Effectiveness, Price, and Simplicity.
Jan 15, 2018 Issue
Nebivolol/Valsartan (Byvalson) for Hypertension
Nebivolol/valsartan is an option for the treatment of patients with newly diagnosed or poorly controlled hypertension. Although it offers a new beta-blocker option, no research has demonstrated its benefit over existing treatments.
Nov 15, 2017 Issue
Reslizumab (Cinqair) for Eosinophilic Asthma
Reslizumab is an expensive treatment option for decreasing exacerbations in patients with severe asthma and pronounced eosinophilia. Because of the risk of anaphylaxis, it should only be administered in an appropriate facility by a medical professional. Reslizumab is best considered after other treatments have proved ineffective.
Oct 15, 2017 Issue
Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus
Dulaglutide is an easy-to-use, once-weekly injectable therapy for the treatment of type 2 diabetes in adults. It produces a modest decrease in A1C levels with only a small risk of severe hypoglycemia. The small average weight loss it induces may be an advantage for some patients.
Sep 15, 2017 Issue
Glycopyrrolate (Seebri Neohaler) for Maintenance Therapy in Patients with COPD
Glycopyrrolate is a safe option for maintenance treatment to prevent moderate to severe exacerbations in patients with moderate to severe COPD, with only mild and rare adverse effects.
Aug 15, 2017 Issue
Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus
ixisenatide is an easy-to-use, once-daily injectable therapy for the treatment of type 2 diabetes in adults. It is at least as effective as exenatide at reducing A1C and body weight, with similar rates of gastrointestinal adverse effects.
Jun 15, 2017 Issue
Idarucizumab (Praxbind) for Dabigatran (Pradaxa) Anticoagulant Reversal
Idarucizumab is the only anticoagulant reversal agent for dabigatran. Because of its high cost and limited data regarding clinical benefit, therapy should be reserved for patients taking dabigatran who have life-threatening bleeding or are in need of emergency surgery.
May 15, 2017 Issue
Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C
Sofosbuvir/velpatasvir is an effective treatment for patients with HCV and has minimal adverse effects. It is the preferred treatment for patients with genotype 2 or 3. As with other curative treatments, it is very expensive.
Apr 15, 2017 Issue
Albiglutide (Tanzeum) for Diabetes Mellitus
Reductions in A1C are less with albiglutide than with the first-line therapy metformin, and albiglutide costs significantly more than metformin and sulfonylureas. Albiglutide's ability to reduce diabetes-related morbidity and major cardiovascular events is unknown.
Mar 15, 2017 Issue
Elbasvir/Grazoprevir (Zepatier) for Hepatitis C Virus Infection
Elbasvir/grazoprevir is a safe and effective treatment for HCV genotypes 1 and 4, with or without compensated cirrhosis or HIV-1 coinfection. Patients with renal impairment, including those on hemodialysis, can use the medication.
Feb 15, 2017 Issue
Rifaximin (Xifaxan) for Irritable Bowel Syndrome
Rifaximin has good overall tolerability. A relatively short course of treatment results in sustained clinical benefit for at least 10 weeks, eliminating the need for continued therapy, with an NNT of 10. However, it is expensive and should be reserved for patients who cannot tolerate or did not respond to more affordable therapies.